Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA.
For further information, please visit www.activebiotech.com.
Aerocrine AB is a clinically based medical technology company that leads the way in the development of devices for monitoring inflammation through the measurement of gaseous markers. The company was founded in 1997 by scientists from the prestigious Karolinska Institute in Sweden and has its headquarters in Solna, Stockholm. The founders were the first to identify nitric oxide (NO) as a marker of inflammation. Today, this strong scientific heritage is supported by an international network of clinical advisors as well as an experienced and efficient management team, which is bringing innovative ideas into clinical practice. Aerocrine holds a comprehensive patent portfolio, including eleven issued patents in the USA, with patents pending.
Affibody AB is a leading company in the development of affinity ligands and technologies for use in biotherapy and biotechnology. Within its Biotherapy division, Affibody develops therapeutic agents for use as biopharmaceuticals, for medical imaging and for therapeutic apheresis. The Biotechnology division commercializes Affibody® molecules for various biotechnology applications such as sample preparation, protein detection methods, in vitro diagnostics and separation of biomolecules.
A key component of Affibody's technology is the Affibody® molecule, a small robust protein which can be designed to bind to any other target protein. Affibody® molecules mimic the function of monoclonal antibodies and the unique properties of Affibody® molecules make them a superior choice for a wide range of biotechnological and biotherapeutic applications.
The business model balances short-term revenue with the prospects of long-term value. Affibody's current commercial partners include Agilent Technologies, Astra Tech, GE Healthcare, Asahi Kasei, Finnzymes and Mabtech.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and Karolinska Institutet in Stockholm. Among the owners of Affibody AB are the investment companies HealthCap, Schroder Ventures Life Sciences and Investor Growth Capital. Affibody is based on Stockholm, Sweden and has 50 employees.
Further information is found on: http://www.affibody.com/
AnaMar has its primary focus on destructive joint diseases (RA&OA). Through agreements with world leading research groups, we have access to and we actively develop unique concepts. We aim to be the leading developers of drug candidates (currently 5 in development) and biomarkers (currently 2 on the market) within the field of cartilage damage in destructive joint diseases
Cellectricon provides advanced chip-based technologies and products for the discovery of new drugs. The company owns 10 patent families within such areas as high throughput electrophysiology, patch clamping, microfabrication and electroporation. The first product, Dynaflow, has already been adopted by 8 out of 10 of the world's largest pharmaceutical companies. Dynaflow enables significant productivity increase in the discovery of drugs targeting ion channel receptors.
Atherosclerosis is the underlying cause of 50 % of all mortality in the western society and the world-wide expenditure of cardiovascular disease (CVD)-drugs alone exceeds $300 billion per year.
Clinical Gene Networks AB (CGN) was founded based on the AtheroCode, a technology platform applying a system biological approach on the combination of genomic single nucletide polymorphism and expression data from unique CVD-patient cohorts and animal and cell-based model systems of atherosclerosis.
The AtheroCode database is to our knowledge the largest database of its kind related to cardiovascular disease (CVD) and atherosclerosis in the world today.
Using the AtheroCode database CGN now applies:
- computer-supported algorithms for gene and protein network identification to develop the first generation of atherosclerosis drugs.
- machine-learning techniques for feature-selection to identify superior biomarkers and diagnostics predicting CVD and atherosclerosis ahead of clinical manifestations.
The AtheroCode also sets the stage to drastically improve the evaluation of CVD-drug candidates performed by pharmaceutical and biomedical companies.
LinkMed AB is a Life Science Investment Company (not fund) directed to development of world class innovations in BioMed, BioTech and MedTech. LinkMed has a very active "Managing owner role" and is directly involved in the development process from early phases (start ups) to early expansion.
Today, the LinkMed portfolio consists of ten companies.